Advertisement
Advertisement
U.S. Markets open in 8 hrs 33 mins
Advertisement
Advertisement
Advertisement
Advertisement

Enochian Biosciences, Inc. (ENOB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.58-0.26 (-2.94%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.84
Open8.88
Bid0.00 x 900
Ask0.00 x 900
Day's Range8.20 - 8.88
52 Week Range2.60 - 12.99
Volume151,420
Avg. Volume256,064
Market Cap408.523M
Beta (5Y Monthly)0.30
PE Ratio (TTM)N/A
EPS (TTM)-0.23
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month

    Company encouraged by clear path to IND in near-term following its review of the FDA’s Center for Biologics Evaluation and Research written commentsLOS ANGELES, Oct. 18, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an Investigator Pre-Investigational New Drug (IND) process following receipt of written comments from the U.S. Food and Drug A

  • GlobeNewswire

    Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity

    LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Peter Piot has resigned as Chairperson of the Respiratory Diseases Scientific Advisory Board due to important responsibilities advising a major governmental organization on COVID-19 that creates a conflict. “I remain very impressed by, and enthusiastic about, the innovative science and potenti

  • GlobeNewswire

    Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

    LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference. Dr. Mark Dybul, CEO will participate in a Fireside Chat with H.C. Wainwright’s Patrick Trucchio, Managing Director and Senior Healthcare Analyst to discuss Enochian BioScienc

Advertisement
Advertisement